Cortisone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Cortisone
Accession Number
DB14681
Description

A naturally occurring glucocorticoid. It has been used in replacement therapy for adrenal insufficiency and as an anti-inflammatory agent. Cortisone itself is inactive. It is converted in the liver to the active metabolite hydrocortisone. (From Martindale, The Extra Pharmacopoeia, 30th ed, p726)

Type
Small Molecule
Groups
Experimental
Structure
Thumb
Weight
Average: 360.444
Monoisotopic: 360.193674006
Chemical Formula
C21H28O5
Synonyms
  • 11-dehydro-17-hydroxycorticosterone
  • 17alpha,21-Dihydroxy-4-pregnene-3,11,20-trione
  • 17α,21-dihydroxy-4-pregnene-3,11,20-trione
  • 4-pregnene-17α,21-diol-3,11,20-trione
  • Cortisona
  • Cortisonum
  • Kendall's compound E
  • Kortison
  • pregn-4-en-17α,21-diol-3,11,20-trione
  • Reichstein's substance Fa
  • Wintersteiner's compound F

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbirateroneThe metabolism of Abiraterone can be increased when combined with Cortisone.
AcalabrutinibThe metabolism of Acalabrutinib can be increased when combined with Cortisone.
AcarboseThe risk or severity of hyperglycemia can be increased when Cortisone is combined with Acarbose.
AceclofenacThe risk or severity of gastrointestinal irritation can be increased when Cortisone is combined with Aceclofenac.
AcemetacinThe risk or severity of gastrointestinal irritation can be increased when Cortisone is combined with Acemetacin.
AcenocoumarolCortisone may increase the anticoagulant activities of Acenocoumarol.
AcetohexamideThe risk or severity of hyperglycemia can be increased when Cortisone is combined with Acetohexamide.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Cortisone is combined with Acetyldigitoxin.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Cortisone is combined with Acetylsalicylic acid.
Adenovirus type 7 vaccine liveThe therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Cortisone.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

ATC Codes
H02AB10 — CortisoneS01BA03 — Cortisone
Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
V27W9254FZ
CAS number
53-06-5
InChI Key
MFYSYFVPBJMHGN-ZPOLXVRWSA-N
InChI
InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-15,18,22,26H,3-8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1
IUPAC Name
(1R,3aS,3bS,9aR,9bS,11aS)-1-hydroxy-1-(2-hydroxyacetyl)-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthrene-7,10-dione
SMILES
[H][[email protected]@]12CC[[email protected]](O)(C(=O)CO)[[email protected]@]1(C)CC(=O)[[email protected]@]1([H])[[email protected]@]2([H])CCC2=CC(=O)CC[[email protected]]12C

References

General References
Not Available
Human Metabolome Database
HMDB0002802
KEGG Drug
D07749
KEGG Compound
C00762
ChemSpider
193441
BindingDB
13739
RxNav
2878
ChEBI
16962
ChEMBL
CHEMBL1499
ZINC
ZINC000004083557
Wikipedia
Cortisone

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4CompletedTreatmentHip Injuries1
4Not Yet RecruitingTreatmentCalcific Tendinitis1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Undifferentiated Leukemia (AUL) / Childhood T Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative1
3Active Not RecruitingTreatmentAnn Arbor Stage IIB Hodgkin Lymphoma / Ann Arbor Stage IIIB Hodgkin Lymphoma / Ann Arbor Stage IV Hodgkin Lymphoma / Ann Arbor Stage IVA Hodgkin Lymphoma / Ann Arbor Stage IVB Hodgkin Lymphoma / Childhood Hodgkin Lymphoma / Classic Hodgkin Lymphoma1
3Active Not RecruitingTreatmentB Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Ph-Like Acute Lymphoblastic Leukemia / Testicular Leukemia1
3Active Not RecruitingTreatmentPlasma Cell Myeloma1
3Active Not RecruitingTreatmentT Acute Lymphoblastic Leukemia / T Lymphoblastic Lymphoma1
3CompletedTreatmentChildhood Lymphocyte-Depleted Classical Hodgkin Lymphoma / Childhood Mixed Cellularity Classical Hodgkin Lymphoma / Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma / Childhood Nodular Sclerosis Classical Hodgkin Lymphoma / Malignant Lymphomas / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral25 MG
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.136 mg/mLALOGPS
logP1.98ALOGPS
logP1.66ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)12.58ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area91.67 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity96.47 m3·mol-1ChemAxon
Polarizability38.95 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-00kf-2910000000-da435cee921dd7b9f8e6
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-03di-0009000000-5d34de066e82cc9f0a41
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-03di-0900000000-24ec04976da03c3f9c77
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-0fdo-4900000000-d0880bfc6f3d80e4aa72
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0009000000-6c22c083c2dfab97a299
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0109000000-48c96b3d1471c5cd6171
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-002r-0914000000-2466a9146383b4265e42
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-0900000000-214430a00501054cc774
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-059j-1900000000-0e23516e07f0baf74c79
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0abj-1900000000-ad0282ab7188d9ec3dc1
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0aba-3900000000-e36e464b157b3e6159f1
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4j-5900000000-fe9092d76099e1e70a4e
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0aou-6900000000-1b218b97a890ac7e8f45
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-03fr-0049000000-3bd424d473bdadd2b9b4
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-03di-0039000000-fd181dfb87e1cbb8ab6f
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-03di-0049000000-7633496a1a53bda21707
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-004i-0009000000-59db5e627634e4be3907
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-004i-0009000000-9781e204df305d722d2d
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-004i-0009000000-0b5e40226163a1a334db
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-004i-0009000000-4c17080e851c04168513
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-004i-0009000000-1f757bd647033f35ce8b
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-03di-0049000000-f6be4039966fcc0fae88
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0009000000-168dd290e0b6d2c0283d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0859000000-17c61fb5c61e802e9cf3
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-1930000000-d8126b5c70edb9054d9b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-08mm-2910000000-8633b075ca01496d1d51
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0597-4910000000-870c02c495b7e43eb832
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-052g-5900000000-4f705736bd665f2e1933
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05oy-7900000000-0c9c65ca4c7b4f8251ec
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-016u-9800000000-c3e7128354f6569b7337
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-016u-9700000000-1bf0707cdc0a5b2c81c7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-1920000000-5811b59a6f57222762d7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-06xw-2910000000-84fec77617e1b7a1648b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03dl-0596000000-e0abadaf09054d046b08
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03xu-0595000000-4f8d30df506ea649fc04
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-03xu-0596000000-4c4ea8a5e8c5c5dc7d93
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-03xu-0596000000-f71bb473cec123157b16
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0329000000-b205426a466686009778
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-3940000000-16be8720b1c49cea9b06
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-1920000000-5811b59a6f57222762d7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-06xw-2910000000-84fec77617e1b7a1648b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03dl-0596000000-e0abadaf09054d046b08
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03xu-0595000000-4f8d30df506ea649fc04
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [PubMed:20482443]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [PubMed:20482443]

Drug created on September 05, 2018 12:17 / Updated on June 12, 2020 11:42

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates